A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER.
Makaleler > Özet · 2018
Yazarlar: Jonathan Wade Goldman, Julien Mazieres, Fabrice Barlesi, Marianna Koczywas, Konstantin H Dragnev, Tuncay GÖKSEL, Alexis B Cortot, Nicolas Girard, Claas Wesseler, Helge Bischoff, Nadal Ernest, Keunchil Park, Shun Lu, Alvaro Taus, Manuel Cobo, Karla Hurt, Alan Chiang, Anwar Hossain, William J John, Luis G Paz-Ares
Journal of Clinical Oncology, SCI Expanded İndekslerine Giren Dergi, Uluslararası, 2018, cilt 36, ss 9025-9025